Smart niosomes of temozolomide for enhancement of brain targeting.

Q1 Engineering Nanobiomedicine Pub Date : 2018-10-11 eCollection Date: 2018-01-01 DOI:10.1177/1849543518805355
Anindita De, Nagasamy Venkatesh, M Senthil, Bharat Kumar Reddy Sanapalli, R Shanmugham, Veera Venkata Satyanarayana Reddy Karri
{"title":"Smart niosomes of temozolomide for enhancement of brain targeting.","authors":"Anindita De, Nagasamy Venkatesh, M Senthil, Bharat Kumar Reddy Sanapalli, R Shanmugham, Veera Venkata Satyanarayana Reddy Karri","doi":"10.1177/1849543518805355","DOIUrl":null,"url":null,"abstract":"<p><p>Drug delivery to the brain is challenging because of the low permeability of blood-brain barrier, and therefore, optimum concentration of chemotherapeutics in the target area specifically for glioblastoma, an aggressive brain tumor, opens a new path of research. To achieve the goal, the oral alkylating agent temozolomide was incorporated into niosomes, and the surface was modified with chlorotoxin, a small 36 amino acid peptide discovered from the venom of scorpion <i>Leiurus quinquestriatus</i>. Active targeting using nanosized particles facilitates an increase in the accumulation of drugs in the cerebri by 3.04-folds. Temozolomide-loaded niosomes were prepared using conventional thin-film hydration method and characterized. Niosomes coated with chlorotoxin were produced with the size of 220 ± 1.45 nm with an entrapment efficiency of 79.09 ± 1.56%. Quantitative tissue distribution studies indicate enhanced permeation of the drug into the brain because of surface modification with less deposition in the highly perfused organs.</p>","PeriodicalId":56366,"journal":{"name":"Nanobiomedicine","volume":"5 ","pages":"1849543518805355"},"PeriodicalIF":0.0000,"publicationDate":"2018-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/e3/10.1177_1849543518805355.PMC6187422.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanobiomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1849543518805355","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Engineering","Score":null,"Total":0}
引用次数: 0

Abstract

Drug delivery to the brain is challenging because of the low permeability of blood-brain barrier, and therefore, optimum concentration of chemotherapeutics in the target area specifically for glioblastoma, an aggressive brain tumor, opens a new path of research. To achieve the goal, the oral alkylating agent temozolomide was incorporated into niosomes, and the surface was modified with chlorotoxin, a small 36 amino acid peptide discovered from the venom of scorpion Leiurus quinquestriatus. Active targeting using nanosized particles facilitates an increase in the accumulation of drugs in the cerebri by 3.04-folds. Temozolomide-loaded niosomes were prepared using conventional thin-film hydration method and characterized. Niosomes coated with chlorotoxin were produced with the size of 220 ± 1.45 nm with an entrapment efficiency of 79.09 ± 1.56%. Quantitative tissue distribution studies indicate enhanced permeation of the drug into the brain because of surface modification with less deposition in the highly perfused organs.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用于增强脑靶向性的替莫唑胺智能新体。
由于血脑屏障的低通透性,向脑部给药具有挑战性,因此,针对胶质母细胞瘤这种侵袭性脑肿瘤,如何在靶区实现化疗药物的最佳浓度开辟了一条新的研究道路。为了实现这一目标,研究人员将口服烷化剂替莫唑胺加入到niosomes中,并用氯毒素修饰其表面,氯毒素是从蝎子Leiurus quinquestriatus的毒液中发现的一种36个氨基酸的小肽。使用纳米颗粒进行主动靶向治疗可使药物在大脑中的蓄积量增加 3.04 倍。采用传统的薄膜水合法制备了替莫唑胺载药的niosomes,并对其进行了表征。制备出的包覆氯毒素的niosomes尺寸为220 ± 1.45 nm,包封效率为79.09 ± 1.56%。定量组织分布研究表明,由于表面改性,药物在脑部的渗透性增强,而在高灌注器官中的沉积较少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nanobiomedicine
Nanobiomedicine Biochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
6.80
自引率
0.00%
发文量
1
审稿时长
14 weeks
期刊介绍: Nanobiomedicine is an international, peer-reviewed, open access scientific journal that publishes research in nanotechnology as it interfaces with fundamental studies in biology, as well as its application to the fields of medicine. Nanobiomedicine covers all key aspects of this research field, including, but not limited to, bioengineering, biophysics, physical and biological chemistry, and physiology, as well as nanotechnological applications in diagnostics, therapeutic application, preventive medicine, drug delivery, and monitoring of human disease. Additionally, theoretical and modeling studies covering the nanobiomedicine fields will be considered. All submitted articles considered suitable for Nanobiomedicine are subjected to rigorous peer review to ensure the highest levels of quality. The review process is carried out as quickly as possible to minimize any delays in the online publication of articles. Submissions are encouraged on all topics related to nanobiomedicine, and its clinical applications including but not limited to: Nanoscale-structured biomaterials, Nanoscale bio-devices, Nanoscale imaging, Nanoscale drug delivery, Nanobiotechnology, Nanorobotics, Nanotoxicology, Nanoparticles, Nanocarriers, Nanofluidics, Nanosensors (nanowires, nanophotonics), Nanosurgery (dermatology, gastroenterology, ophthalmology, etc), Nanocarriers commercialization of nanobiomedical technologies, Market trends in the nanobiomedicine space, Ethics and regulatory aspects of nanobiomedicine approval, New perspectives of nanobiomedicine in clinical diagnostics, BioMEMS, Nano-coatings, Plasmonics, Nanoscale visualization.
期刊最新文献
Mesoporous silica nano-adjuvant triggers pro-inflammatory responses in Caco-2/peripheral blood mononuclear cell (PBMC) co-cultures Gold nanotheranostics: future emblem of cancer nanomedicine. Green synthesis of gold nanoparticles using Acai berry and Elderberry extracts and investigation of their effect on prostate and pancreatic cancer cells. Effect of intracellular uptake of nanoparticle-encapsulated trehalose on the hemocompatibility of allogeneic valves in the VS83 vitrification protocol. Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1